Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Safety and PK of Topical ANR-001.1 (Latanoprost + Minoxidil) in Male Androgenetic Alopecia
NCT05864885Phase 1Unknown
- Sponsor
- Aneira Pharma
- Start
- Jun 2023
- Primary completion
- Jul 2023
- Modality
- Orthosteric Ligands
01
Overview
Phase 1, open-label, single-arm trial of latanoprost and minoxidil in androgenetic alopecia (AGA), sponsored by Aneira Pharma. Primary endpoints: Maximum Plasma Concentration at 7 days, Time to Maximum Plasma Concentration at 7 days and 6 more. Status: unknown.
02
Drugs
latanoprostminoxidil
03
Conditions
androgenetic alopecia (AGA)
Beyond the preview
Go deeper on NCT05864885.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05864885.